Washington, D.C. – 31.05.2026: A new drug called Daraxonrasib has shown promising results in clinical trials for the treatment of metastatic pancreatic cancer. The experimental drug targets a mutation in the KRAS protein, which is present in over 90 percent of all pancreatic carcinomas and has so far been difficult to treat. In a randomized study with 500 patients, Daraxonrasib increased median survival time to 13.2 months compared to 6.7…
News subscription
Three news articles per day are free. For further articles and the three-day overview, please continue with the News subscription. All plans are one-time payments with no automatic renewal and no further charges.